44 results on '"Chhetri, Rakchha"'
Search Results
2. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
3. TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
4. Characteristics and Outcomes of Radiation Therapy-Related Myeloid Neoplasms
5. Comparable Survival Following Allogeneic Haematopoietic Stem Cell Transplant Utilising HLA-Matched Versus Alternative Donors: A Single-Centre Retrospective, Consecutive Cohort Analysis
6. Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53therapy-Related Myeloid Neoplasm Patients with Poor Outcome
7. Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms
8. Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies
9. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
10. Frequency of Chromosomal Translocations Are Significantly Higher in Therapy Related Myeloid Neoplasm As Compared to Primary MDS
11. Hypomethylating Therapy Does Not Improve Outcome of Therapy-Related Myeloid Neoplasm Including TP53 Mutated and Complex Karyotype Subgroups
12. Unexpected High Frequency of Pathogenic Germline Variants in Older Adults with Primary Myelodysplastic Syndrome
13. Outcome of Therapy-Related Myeloid Neoplasms with Venetoclax-Based Therapy
14. T-MDS Is a Distinct Clinical and Pathological Entity Characterized By Better Survival Compared to t-AML
15. High Prevalence of IDH Mutation in Myeloid Neoplasm with Concomitant Autoimmune Rheumatic Disorders
16. Single-Hit TP53mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History
17. TP53mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
18. Therapy-Related Myeloid Neoplasm Has a Distinct Pro-Inflammatory Bone Marrow Microenvironment and Delayed DNA Damage Repair
19. Burden of Cardiovascular Events and Bleeding Is High in Myelodysplastic Syndromes
20. Deleterious Germline Variants, Especially in the DNA Repair Pathway, Are Common in Patients with Non-Related Multiple Cancers, One of Them Being Hematological Malignancy
21. An Observational Study of the Prescribing Practices and Patient Reported Outcomes Measures in Older People with Myelodysplastic Syndrome
22. Aberrant Bone Marrow Microenvironment in Therapy Related Myeloid Neoplasm (t-MN)
23. The Burden of Clinically Significant Bleeding, Thrombocytopenia and Platelet Transfusions in Myelodysplastic Syndromes
24. The Mutation Profile of Myelodysplastic Syndrome Associated with Auto-Immune Rheumatological Disorders
25. Genetic Predisposition to Therapy-Related Myeloid Neoplasm By Rare, Deleterious Germline Variants in DNA Repair Pathway and Myeloid Driver Genes
26. Geriatric Assessment in Older People with Myelodysplasia Is Predictive of Azacitidine Therapy Completion and Survival: A Prospective Interventional Study at the Royal Adelaide Hospital
27. Causative Organisms and Resistance Patterns of Infection in Patients with Myelodysplastic Syndrome (MDS): A 20 Year Retrospective Analysis
28. Red Cell Alloimmunisation Is Associated with Increased Red Cell Transfusion Requirements in Myelodysplastic Syndrome
29. Therapy-Related Myeloid Neoplasms (T-MN) and Primary MDS (PMDS) Patients with Very Low (VL) or Low (L) IPSS-R Score Share Clinical and Biological Characteristics and Have Similar Outcome
30. IDHMutant Myeloid Neoplasms are Associated with Seronegative Rheumatoid Arthritis and Innate Immune Activation
31. The Frequency of Genetic Mutations in T-MN Is High and Comparable to Primary MDS but the Spectrum Is Different
32. RBC-Transfusion Dependency Improves the Prognostic Value of the Revised-IPSS in MDS Patients: Analysis of South Australian and Dusseldorf MDS Registries
33. Single-Hit TP53mutIs Associated with Poor Outcomes in Therapy-Related but Not De NovoMyelodysplastic Syndromes: Importance of Clinical History
34. High Prevalence of IDHMutation in Myeloid Neoplasm with Concomitant Autoimmune Rheumatic Disorders
35. RBC Alloimmunization Burden Is High in Regularly RBC-Transfused Myelodysplastic Syndrome (MDS) Patients: A Report from South Australian-MDS Registry
36. Presence of Rare Germline Variants in Fanconi Anaemia Pathway Genes Confers a Poor Prognosis Comparable to TP53 Mutations in Therapy-Related Myeloid Neoplasms
37. Red Cell Alloimmunisation Is Associated with Development of Autoantibodies and Increased Red Cell Transfusion Requirements in Myelodysplastic Syndromes (MDS)
38. A Geriatric Screening Tool (G8) Provides an Independent Prognostic Index for Azacitidine Treated Elderly MDS Patients
39. Inclusion of RBC-Transfusion Dependency Can Improve the Prognostic Value of Revised-IPSS in MDS Patients
40. TP53Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
41. Transfusion Dependency Is Associated With Inferior Survival Even In Very Low and Low Risk IPSS-R Patients
42. Presence of Rare Germline Variants in Fanconi Anaemia Pathway Genes Confers a Poor Prognosis Comparable to TP53Mutations in Therapy-Related Myeloid Neoplasms
43. Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies
44. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.